Copanlisib (BAY806946)

Phase 1/2Terminated

1 views this week 0 watching💤 Quiet

Interest: 21/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Relapsed or Refractory Solid Tumors or Lymphoma in Children

Conditions

Relapsed or Refractory Solid Tumors or Lymphoma in Children, Neuroblastoma, Osteosarcoma, Rhabdomyosarcoma, Ewing Sarcoma

Trial Timeline

Apr 30, 2018 → Feb 1, 2023

NCT ID

NCT03458728

About Copanlisib (BAY806946)

Copanlisib (BAY806946) is a phase 1/2 stage product being developed by Bayer for Relapsed or Refractory Solid Tumors or Lymphoma in Children. The current trial status is terminated. This product is registered under clinical trial identifier NCT03458728. Target conditions include Relapsed or Refractory Solid Tumors or Lymphoma in Children, Neuroblastoma, Osteosarcoma.

What happened to similar drugs?

2 of 20 similar drugs in Relapsed or Refractory Solid Tumors or Lymphoma in Children were approved

Approved (2) Terminated (2) Active (16)

✅Acalabrutinib capsuleAstraZenecaApproved

✅Drug: Carfilzomib + Dexamethasone + Drug: Carfilzomib + Lenalidomide + DexamethasoneAmgenApproved

🔄CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)CelltrionPhase 3

🔄Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3

🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3

🔄Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclaxAbbViePhase 3

🔄AZD0120 + Daratumumab + Carfilzomib + Dexamethasone + Bortezomib + PomalidomideAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03458728	Phase 1/2	Terminated	Apr 30, 2018	Feb 1, 2023	Relapsed or Refractory Solid Tumors or Lymphoma in Children

Competing Products

20 competing products in Relapsed or Refractory Solid Tumors or Lymphoma in Children

See all competitors

Product	Company	Stage	Hype Score
mRNA-2752 + Durvalumab	AstraZeneca	Phase 1	29
mRNA-2736	Moderna	Phase 1	0
mRNA-2808	Moderna	Phase 2	0
mRNA-2416	Moderna	Phase 2	0
Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide	Eli Lilly	Phase 1/2	32
agenT-797	MiNK Therapeutics	Phase 1	19
VIP152 + BTKi	Vincerx Pharma	Phase 1	11
eFT508 + Avelumab	eFFECTOR Therapeutics	Phase 2	25
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)	Celltrion	Phase 3	47
AC220	Daiichi Sankyo	Phase 1	29
Valemetostat Tosylate	Daiichi Sankyo	Phase 2	39
Linsitinib	Astellas Pharma	Phase 2	35
AGS67E	Astellas Pharma	Phase 1	29
Mitoxantrone Hydrochloride Liposome & Enlonstobart	Sun Pharmaceutical	Phase 1/2	39
Lenvatinib	Eisai	Phase 2	35
Tazemetostat	Eisai	Phase 2	35
Tazemetostat	Eisai	Phase 1	29
Eribulin mesylate	Eisai	Phase 2	35
ME-401	Kyowa Kirin	Phase 1	29
KK2845_1 + KK2845_2 + KK2845_3 + KK2845_4 + KK2845_5 + KK2845_6	Kyowa Kirin	Phase 1	36